Our Partner Brands
Trusted Global Brands in Life Science Research

Abbexa
Supplier of antibodies, proteins, ELISA kits and enzymes for life science research.
Abbexa is based at the world-renowned Cambridge Science Park, in Cambridge, UK. They are a supplier of biological tools for the life sciences, pharmaceutical development and biotechnology sectors. Abbexa provides the scientific community with primary antibodies, secondary antibodies, proteins, ELISA kits and enzymes as well as other kits and tools for use in research. In collaboration with various laboratories around the world, they strive to develop relevant, high quality, tested products for the biomedical research market.

Micronbrane

Fujirebio Europe
Founded in 1985, the company developed and marketed IVD testing solutions as well as OEM raw materials. Fujirebio is an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care.
Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time.
4.

Bio-Helix
Bio-Helix has been focusing on providing the best bio-reagents for life science researchers all over the world since 2007. Our products, to name a few, include DNA markers, protein markers, pre-cast protein gel, nucleic acid purification, PCR reagents and so on. Working together with scientists in the lab around the world and continuing efforts of quality improvement, we begin to gain trusts and appraises from customers. The brand, spreading in more than forty countries, has become a trustworthy and welcome brand of reagents in laboratories of life science.

QuidelOrtho
QuidelOrtho Corporation is a publicly traded American in vitro diagnostics company headquartered in San Diego, formed through the merger of Quidel and Ortho Clinical Diagnostics. Founded initially by Dr. David H. Katz in 1979, Quidel gained prominence for launching the first emergency use authorized rapid COVID‑19 antigen test in the U.S. in May 2020. In December 2021, it expanded significantly via a $6 billion acquisition of Ortho Clinical Diagnostics, enhancing its diagnostic capabilities across immunoassays, molecular testing, immunohematology, and clinical chemistry. As of December 31, 2023, QuidelOrtho reported approximately 7,100 employees and revenue of around US $3 billion
